These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
433 related items for PubMed ID: 10444025
1. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. J Lab Clin Med; 1999 Aug; 134(2):124-32. PubMed ID: 10444025 [Abstract] [Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent. Selgas R, del Peso G, Bajo MA, Molina S, Cirugeda A, Sánchez-Tomero JA, Castro MJ, Castro MA, Vara F. J Nephrol; 2001 Feb; 14(4):270-4. PubMed ID: 11506249 [Abstract] [Full Text] [Related]
4. Growth factors in continuous ambulatory peritoneal dialysis effluent. Their relation with peritoneal transport of small solutes. Lai KN, Lai KB, Szeto CC, Lam CW, Leung JC. Am J Nephrol; 1999 Feb; 19(3):416-22. PubMed ID: 10393381 [Abstract] [Full Text] [Related]
5. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Stompór T, Zdzienicka A, Motyka M, Dembińska-Kieć A, Davies SJ, Sulowicz W. Perit Dial Int; 2002 Feb; 22(6):670-6. PubMed ID: 12556068 [Abstract] [Full Text] [Related]
6. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Park SH, Lee EG, Kim IS, Kim YJ, Cho DK, Kim YL. Perit Dial Int; 2004 Feb; 24(2):115-22. PubMed ID: 15119632 [Abstract] [Full Text] [Related]
7. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis. Kariya T, Nishimura H, Mizuno M, Suzuki Y, Matsukawa Y, Sakata F, Maruyama S, Takei Y, Ito Y. Am J Physiol Renal Physiol; 2018 Feb 01; 314(2):F167-F180. PubMed ID: 28978530 [Abstract] [Full Text] [Related]
8. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. van Esch S, Zweers MM, Jansen MA, de Waart DR, van Manen JG, Krediet RT. Perit Dial Int; 2004 Feb 01; 24(6):554-61. PubMed ID: 15559485 [Abstract] [Full Text] [Related]
9. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. (Grupo de Estudios Peritoneales de Madrid). del Peso G, Selgas R, Bajo MA, Fernández de Castro M, Aguilera A, Cirugeda A, Jiménez C. Adv Perit Dial; 2000 Feb 01; 16():85-9. PubMed ID: 11045267 [Abstract] [Full Text] [Related]
10. Peritoneal transport characteristics with glucose polymer based dialysate. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, Hiralall JK, de Waart DR, Struijk DG, Krediet RT. Kidney Int; 1996 Sep 01; 50(3):979-86. PubMed ID: 8872974 [Abstract] [Full Text] [Related]
11. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Lin CY, Chen WP, Yang LY, Chen A, Huang TP. Am J Nephrol; 1998 Sep 01; 18(6):513-9. PubMed ID: 9845827 [Abstract] [Full Text] [Related]
12. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Ha H, Cha MK, Choi HN, Lee HB. Perit Dial Int; 2002 Sep 01; 22(2):171-7. PubMed ID: 11990400 [Abstract] [Full Text] [Related]
13. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide? Douma CE, de Waart DR, Struijk DG, Krediet RT. Clin Nephrol; 1996 May 01; 45(5):295-302. PubMed ID: 8738660 [Abstract] [Full Text] [Related]
14. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Smit W, de Waart DR, Struijk DG, Krediet RT. Perit Dial Int; 2000 May 01; 20(5):557-65. PubMed ID: 11117247 [Abstract] [Full Text] [Related]
15. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution. Günal AI, Celiker H, Ustundag B, Akpolat N, Dogukan A, Akcicek F. J Nephrol; 2003 May 01; 16(2):225-30. PubMed ID: 12768069 [Abstract] [Full Text] [Related]
16. The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD. Douma CE, de Waart DR, Struijk DG, Krediet RT. Kidney Int; 1997 Jun 01; 51(6):1885-92. PubMed ID: 9186879 [Abstract] [Full Text] [Related]
17. A chronic inflammatory infusion model of peritoneal dialysis in rats. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. Perit Dial Int; 2001 Jun 01; 21 Suppl 3():S368-72. PubMed ID: 11887858 [Abstract] [Full Text] [Related]
18. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, Kim CD, Park SH, Yoon KW. Perit Dial Int; 2008 Jun 01; 28 Suppl 3():S101-6. PubMed ID: 18552237 [Abstract] [Full Text] [Related]
19. A comparison between 1.36% and 3.86% glucose dialysis solution for the assessment of peritoneal membrane function. Smit W, Langedijk MJ, Schouten N, van den Berg N, Struijk DG, Krediet RT. Perit Dial Int; 2000 Jun 01; 20(6):734-41. PubMed ID: 11216568 [Abstract] [Full Text] [Related]
20. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution. Günal AI, Celiker H, Akpolat N, Ustündag B, Duman S, Akcicek F. Perit Dial Int; 2002 Jun 01; 22(3):301-6. PubMed ID: 12227386 [Abstract] [Full Text] [Related] Page: [Next] [New Search]